After initial hit identification, follow-up activities may include fragment hit expansion by leveraging our integrated fragment-based drug discovery platform, built on our joint capabilities in medicinal chemistry, computational chemistry, X-ray crystallography, biophysical validation, biochemical and cell-based assays, in vitro ADME, etc. Protein NMR spectroscopy and protein X-ray crystallography can verify compound binding and gain insights into the interactions with the target protein. In addition, the WAC™ column lasts several months and can be reused to rank acquired or synthesized analogs rapidly.
